
## Figure S1

### Patient population

- Advanced HER2-negative breast cancer
- Germline *BRCA1* or *BRCA2* mutation
- ≤2 prior lines cytotoxic therapy for metastatic disease
- ≤1 prior lines of platinum; no progression ≤12 months of completing

# Stratification factors

- Hormone receptor expression
- Prior platinum
- · CNS metastasis



Optional openlabel crossover to veliparib

#### Primary endpoint: Investigator-assessed PFS per RECIST v1.1

## 21-day cycles

- · Carboplatin: AUC 6 on day 1
- Paclitaxel: 80 mg/m<sup>2</sup> on days 1, 8, 15
- Veliparib or placebo: 120 mg BID on days –2 to 5
- Plasma cfDNA harvested at cycles 1, 3 and at progression during blinded portion